Evidence map›Paper›PMID 42221364›Full record

Trial reportOpen forum infectious diseases2026

Early Experience With Beta-Lactam Therapeutic Drug Monitoring in an Outpatient Parenteral Antimicrobial Therapy (OPAT) Program.

Kemar O Barrett, Christina G Rivera, Omar Abu Saleh, Margaret Pertzborn, Sara E Ausman, Andrew D Rule, Kellie Arensman Hannan, Ryan W Stevens, Erin F Barreto

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kemar O BarrettDivision of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0009-0006-5655-9737
Christina G RiveraDepartment of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-8308-3264
Omar Abu SalehDivision of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0003-4955-5544
Margaret PertzbornDepartment of Pharmacy, Mayo Clinic Health System, Eau Claire, Wisconsin, USA.ORCID https://orcid.org/0000-0002-9898-7266
Sara E AusmanDepartment of Pharmacy, Mayo Clinic Health System, Eau Claire, Wisconsin, USA.ORCID https://orcid.org/0000-0001-7267-2656
Andrew D RuleDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Kellie Arensman HannanDepartment of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-0200-1782
Ryan W StevensDepartment of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-5050-6689
Erin F BarretoDepartment of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe early experience with beta-lactam therapeutic drug monitoring (TDM) in a high-volume outpatient parenteral antimicrobial therapy program. In selected patients, TDM informed dose optimization and toxicity mitigation. Illustrative cases highlight feasibility and emerging lessons supporting beta-lactam TDM in outpatient care.

Indexed as

beta-lactam antibioticscefepimeoutpatient parenteral antimicrobial therapypharmacokineticstherapeutic drug monitoring

Identifiers

PMID42221364
PMCPMC13218442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.